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Background and Purpose—The pathogenic link between patent foramen ovale (PFO) and stroke remains unknown in most
cases. We investigated the association between inherited thrombophilic disorders and PFO-related strokes in a series of
young adults in the setting of a case-control study.
Methods—We investigated 125 consecutive subjects (age, 34.77.3 years) with ischemic stroke and 149 age- and
sex-matched control subjects. PFO was assessed in all patients with transcranial Doppler sonography with intravenous
injection of agitated saline according to a standardized protocol. Genetic analyses for the factor V (FV)G1691A mutation,
the prothrombin (PT)G20210A variant, and the TT677 genotype of methylenetetrahydrofolate reductase (MTHFR) were
performed in all subjects.
Results—A pathogenic role of PFO was presumed in 36 patients (PFO). Interatrial right-to-left shunt either was not
detected or was considered unrelated to stroke occurrence in the remaining 89 patients (PFO). The PTG20210A variant
was more frequent in the PFO group compared with control subjects and the PFO group (PFO versus control
subjects, 11% versus 2%; 95% CI, 0.04 to 0.94; PFO versus PFO, 11% versus 1.1%; 95% CI, 1.09 to 109;
P0.047). A similar distribution was observed for subjects carrying either the PTG20210A variant or the FVG1691A mutation
(PFO versus control subjects, 19.4% versus 5.3%; 95% CI, 0.08 to 0.75; PFO versus PFO, 19.4% versus 3.3%;
95% CI, 1.45 to 26.1; P0.021). Combined thrombophilic defects were observed in 3 subjects of the PFO group, in
2 control subjects (8.3% versus 1.3%; 95% CI, 0.01 to 0.66; P0.015), and in 0 subjects in the PFO group. A trend
toward a difference in the frequency of the FVG1691A mutation between PFO and control subjects was found after
bivariate analysis (11% versus 3.3%; P0.068) but not after multinomial logistic regression analysis. No significant
association was found in the distribution of the TT MTHFR genotype in the 3 groups.
Conclusions—In young adults, the PTG20210A variant and, to a lesser extent, the FVG1691A mutation may represent risk factors
for PFO-related cerebral infarcts. A role of systemic thrombophilic disorders in the pathogenesis of this specific subtype
of stroke may be hypothesized. (Stroke. 2003;34:28-33.)
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Over the last decade, patent foramen ovale (PFO) hasbeen identified as an independent risk factor for cerebral
infarct, particularly in young adults with cryptogenic
stroke.1–4 However, the causal relationship is not established,
and the pathophysiological process linking this abnormality
to stroke remains elusive in most cases. Paradoxical embo-
lism from the peripheral venous system,5 embolization from
thrombi formed within the atrial septum,6,7 and the formation
of thrombus as a result of transient atrial arrhythmias have
been advocated.8 Furthermore, the detection of PFO in a
stroke patient with an otherwise unexplained infarct does not
necessarily identify the cause of stroke. Owing to the uncer-
tainty about the mechanism of brain ischemia, secondary
prevention for patients with PFO who have had a stroke is a
subject of considerable debate.
Recently, sparse observations suggested that a disequilib-
rium of the hemostatic system toward a clotting diathesis may
increase the propensity to form an unstable thrombus and
affect the risk of cerebral embolism in the presence of
interatrial septal abnormalities. The possibility that patients
with PFO-related stroke have an underlying hypercoagulable
state has potential implications for the understanding of the
pathophysiological process and identification of the most
appropriate therapeutic strategies. Most of the published data
on this issue are either anecdotal9,10 or documented in case
series11–14 and case-control studies not specifically designed
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to test this hypothesis.15–17 Thus, the association of PFO with
inherited prothrombotic disorders in stroke patients remains
to be determined.
The aim of the present study was to systematically explore
such an association and to investigate the role of thrombo-
philic conditions in different pathogenic subtypes of ischemic
stroke. To accomplish this purpose, we undertook a prospec-
tive case-control study including a series of young adults with
first-ever ischemic stroke and a group of control subjects
stratified by age and ethnic and geographic origin.
Subjects and Methods
Patients with first-ever ischemic stroke occurring at45 years of age
who were consecutively admitted to our department between January
1997 and December 2000 were invited to participate in a research
program for the evaluation of gene-environment interactions in the
development of ischemic cerebrovascular disease. From a series of
129 unrelated subjects, 125 were prospectively considered for
participation. Unwillingness to undergo genetic analysis explains the
exclusion of 4 subjects.
A detailed description of the diagnostic workup and the stroke
subtype classification criteria have been presented previously.18
Briefly, the standard protocol included neurological examination,
brain CT and/or MRI scan, extracranial Doppler ultrasonography
with frequency analysis and B-mode imaging, transcranial Doppler
(TCD), 12-lead ECG, transthoracic and/or transesophageal echocar-
diography, and standard blood tests. Coagulation testing, including
prothrombin and activated partial thromboplastin times, antiphos-
pholipid antibodies, fibrinogen, protein C, protein S, activated
protein C resistance, and antithrombin III, was also carried out. MR
angiography and/or conventional angiography of the neck and
cerebral vessels were performed in selected cases. Assessment of
lower extremity venous Doppler was performed whenever the
clinical history and examination justified the suspicion of deep-vein
thrombosis.
One hundred forty-nine subjects from the staff of our hospital with
no known history of vascular disease, matched to the cases by sex
and age in 3-year bands, were invited to participate in the study as
control subjects. Both cases and controls were white and were from
the same geographic area and social status.
Demographic data (age, sex) and history of conventional vascular
risk factors such as hypertension, diabetes mellitus, cigarette smok-
ing, and hypercholesterolemia were assessed in each subject accord-
ing to predefined criteria.18
Genetic analyses for inherited prothrombotic conditions including
the G1691A mutation in the factor V (FV) gene, the G20210A
mutation within the 3-untranslated region of the prothrombin (PT)
gene, and the C677T mutation in the methylenetetrahydrofolate
reductase (MTHFR) gene were performed in both cases and controls.
The study was designed and carried out in observance of the
ethical principles established by the local Institutional Guidelines on
Clinical Investigation. Written, informed consent was provided by all
study participants.
Assessment of PFO
PFO was assessed in all patients with TCD with intravenous
injection of agitated saline. The technique is described in detail
elsewhere.19 Briefly, it consists of the injection of 20 mL of
previously shaken saline as a contrast-enhancing agent into a
peripheral vein while recording the flow velocity of the middle
cerebral artery, insonated through the temporal window on the right
side at a depth of 50 to 60 mm, with a handheld probe. The
appearance of transient spikes on the velocity spectral curve within
10 seconds of the intravenous injection of contrast medium is
considered positive for interatrial right-to-left shunt. The method has
been previously validated in our institution and provides 90%
sensitivity, 100% specificity, and an overall diagnostic accuracy of
95% compared with transesophageal echocardiography. All contrast
TCD studies were performed with a standard TC2020 EME (Nicolet
Biomedical) device equipped with a 2-MHz transducer by 2 experi-
enced examiners (M.M., A.C.) who were unaware of the results of
laboratory investigations.
PFO-Related Infarcts
All patients had a temporal window suitable for TCD investigations.
Interatrial right-to-left shunt was evident in 42 cases (33.6%) as an
isolated abnormality (n35) or in association with the echographic
finding of mitral valve prolapse (n1). The remaining 6 cases were
detected in patients with angiographically proven spontaneous cer-
vical artery dissection (n4), probable atherosclerotic vasculopathy
(n1), and lacunar infarct (n1). Right-to-left shunt was considered
a coincidental finding in these cases, and in the etiologic classifica-
tion, priority was given to the vascular mechanism of stroke. Thus,
after the exclusion of these 6 cases, a total of 36 patients were
entered into the group of PFO-related cerebral infarcts (PFO).
Three of them had deep-vein thrombosis at the time of stroke.
Genetic Analysis
Genomic DNA was isolated from 20°C frozen samples of EDTA-
anticoagulated whole blood through standard DNA extraction. The
G1691A mutation in the FV gene (factor V Leiden) and the
G20210A mutation in the PT gene were determined according to a
standardized multiplex polymerase chain reaction method.20 The
C677T MTHFR genotypes were determined according to the method
of Frosst and coworkers21 with polymerase chain reaction amplifi-
cation and restriction digestion with HinfI to distinguish mutant from
wild-type allele.
Statistical Analysis
Differences in the distribution of baseline categorical variables
between cases and controls and among the PFO group, the PFO
group, and controls were compared with the use of Fisher’s exact test
and Pearson’s 2 test computed by Monte Carlo procedure, respec-
tively. A value of P0.05 on a 1-sided test (for Fisher’s exact test)
and on a 2-sided test (for Pearson’s 2 test) was considered
significant. A multinomial logistic regression model that included
sex, age, hypertension, smoking status, hypercholesterolemia, and
thrombophilic genotypes was used to examine the effect of these
variables in the prediction of group status (PFO, PFO, control).
Diabetes mellitus was not entered into the multiple regression
equations because of the low frequency of this condition in the
present series. Overall model fit for covariates and thrombophilic
genotypes was tested by the likelihood ratio test between the model
with the tested effect and the model without the effect. A value of
P0.05 on the 2-sided likelihood ratio test was considered signifi-
cant. Results are given as odds ratios (ORs) with 95% CIs. The
analyses were undertaken with the SPSS (version 11.1) software
package.
Results
Table 1 shows the prevalence of baseline demographics and
vascular risk factors among patients and controls. As ex-
pected, patients were more often smokers and more often had
hypertension compared with controls, whereas the prevalence
of diabetes mellitus and hypercholesterolemia was not signif-
icantly different between the 2 groups.
Distribution of the Prothrombotic Genotypes in
the Patient Group
The observed distribution of the genotypes closely resembled
those previously reported in other series from Northern
Italy.22,23 The prevalence of subjects carrying at least 1
procoagulant genotype was significantly higher in the group
of patients than in the group of controls (28% versus 18.7%;
P0.049). In contrast, no significant differences were ob-
Pezzini et al Thrombophilic Disorders in PFO-Related Infarcts 29
served in the distribution of the FVG1691A mutation, PTG20210A
variant, and TT MTHFR genotype, as well as the frequency
of subjects carrying either the FVG1691A mutation or the
PTG20210A variant, the FVG1691A mutation or the TT MTHFR
genotype, and the PTG20210A variant or the TT MTHFR
genotype. Finally, the frequency of subjects with a com-
bination of 1 prothrombotic defect did not differ signif-
icantly in the 2 groups. None of the study subjects was
found to be homozygous for the FVG1691A mutation or the
PTG20210A variant. The overall distribution of the thrombo-
philic genotypes is shown in Table 2.
Distribution of the Prothrombotic Genotypes in
the Group of PFO and PFO Patients
A significant difference between the subgroup of PFO
patients and the group of controls was observed in the
distribution of the PTG20210A variant (29.96; df2;
P0.016), the prevalence of subjects carrying either the
FVG1691A mutation or the PG20210A variant (211.6; df2;
P0.003), and the frequency of subjects with a combination
of 1 thrombophilic defect (210.4; df2; P0.013). A
trend toward a difference (25.59; df2; P0.068) in the
distribution of the FVG1691A mutation was also found. Findings
from the bivariate analysis were further investigated in the
multinomial logistic regression model adjusted for demo-
graphic variables (age and sex) and vascular risk factors. The
results were substantially unaltered. However, as opposed to
the PTG20210A variant, the FVG1691A mutation turned out to play
a marginal role in the occurrence of stroke in PFO patients.
Both the PTG20210A variant and the carriership of either the
FVG1691A mutation or the PTG20210A variant were also signifi-
cantly associated in the subgroup of PFO patients compared
with the subgroup of individuals whose cerebral infarct was
unrelated to PFO (PFO) (Table 3). In contrast, the distri-
bution of the prothrombotic genotypes did not differ between
PFO patients and controls (data not shown).
Discussion
The literature on hypercoagulable states in stroke patients
with PFO is scarce and mostly anecdotal. Ours is the first
case-control study exploring the relationship between FV
Leiden, the PTG20210A variant, and the TT MTHFR genotype
and PFO-related cerebral infarcts. The present study provides
evidence that the PTG20210A variant and, to a lesser extent, the
FVG1691A mutation, are associated in the subgroup of PFO
patients, suggesting a role of such disorders in the pathogen-
esis of stroke related to interatrial septal abnormalities. In
contrast, despite the reported association between the ho-
mozygous deficient TT MTHFR genotype and venous throm-
bosis,24,25 the relationship of such a defect with cerebral
ischemia in patients with PFO seems unlikely.
The role of prothrombotic states in patients with PFO-
related stroke has seldom been satisfactorily investigated. Di
TABLE 1. Demographic and Clinical Characteristics of Stroke Patients
and Controls
Characteristic
Stroke Patients
(n125)
Control Subjects
(n149) Crude OR 95% CI P Value*
Age 34.77.3 34.86.1
Sex (male) 68 (54.4) 80 (53.7) 1.029 0.64–1.66 0.562
Smoking 59 (47.2) 40 (26.8) 0.411 0.25–0.68 0.001
Hypertension 18 (14.4) 10 (6.7) 0.428 0.19–0.96 0.029
Diabetes mellitus 2 (1.6) 0 (0.0) 0.207
Hypercholesterolemia 31 (24.8) 30 (20.1) 0.764 0.43–1.35 0.218
MeanSD and number (percentage) are presented for age and categorical variables, respectively.
*P values obtained using 1-sided Fisher’s exact test.
TABLE 2. Distribution of Prothrombotic Genotypes in Stroke Patients and Controls
Stroke Patients
(n125)
Control Subjects
(n149) Crude OR 95% CI P Value*
FVG1691A 6 (4.8) 5 (3.3) 0.689 0.21–2.31 0.381
PTG20210A 5 (4.0) 3 (2.0) 0.493 0.12–1.26 0.269
TT MTHFR 27 (21.6) 23 (15.4) 0.663 0.36–1.23 0.123
FVG1691A or PTG20210A 10 (8) 8 (5.3) 0.652 0.25–1.71 0.263
FVG1691A or TT MTHFR 32 (25.6) 27 (18.1) 0.688 0.39–1.23 0.132
PTG20210A or TT MTHFR 31 (24.8) 26 (17.4) 0.674 0.37–1.21 0.121
FVG1691A or PTG20210A or TT MTHFR 35 (28) 28 (18.7) 0.595 0.34–0.99 0.049
Combined thrombophilic defects 3 (2.4)† 2 (1.3)‡ 0.553 0.09–3.36 0.418
*P values obtained using 1-sided Fisher’s exact test.
†Heterozygosity for the FVG1691A mutationheterozygosity for the PTG20210A variant, heterozygosity for the FVG1691A
mutationTT MTHFR genotype, and heterozygosity for the PTG20210A variantTT MTHFR genotype, respectively.
‡Heterozygosity for the FVG1691A mutationTT MTHFR genotype, and heterozygosity for the PTG20210A variantTT
MTHFR genotype, respectively.
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Tullio et al12 found a significantly higher prevalence of
protein C deficiency among 25 stroke patients with PFO
compared with 195 without PFO. However, the assessment of
right-to-left shunt by transthoracic contrast echocardiography
represents a substantial bias of that study. Barinagarrement-
eria et al13 and Chaturvedi11 obtained similar findings in small
case series, whereas Schwarze et al26 found an increased
prevalence of right-to-left shunts in patients with cerebrovas-
cular accidents and activated protein C resistance compared
with patients without this thrombophilic disorder. It is notable
that a large group of control subjects with no history of stroke
was lacking in all these studies. Furthermore, coagulation
tests did not include specific genetic analyses. Nongenetic
laboratory assays for coagulopathies may be influenced by
various physiological, pharmacological, and hematologic fac-
tors when performed during the acute phase of stroke.27 In
addition, a direct relationship between intracerebral concen-
trations of hemostatic proteins and circulating levels obtained
from peripheral blood samples has never been proved.28
Because none of these reports provided detailed information
on such potential confounding, methodological limitations
are critical for the interpretation of the results. In contrast, the
use of genetic analyses, which are not likely to be affected by
the acute-phase response, and the recruitment of a large
cohort of control subjects represent the strengths of our study.
Given its character of association study, the present report
can provide no data concerning the biological process linking
coagulopathies and cerebral ischemia in patients with inter-
atrial right-to-left shunt. Thus, any causal relationship can be
only speculative.
Although paradoxical embolism is the favored hypothesis,
deep-vein thrombosis in stroke patients with PFO is usually
undetectable.29 However, sparse reports suggest that this
pathomechanism has probably been underestimated.30 Re-
cently, Cramer and coworkers31 diagnosed paradoxical em-
bolism in 29% of patients in a small series of subjects with
cryptogenic stroke and suggested that deep-vein thrombosis
may be missed in a significant proportion of cases if an
extensive study of pelvic and calf vein is not performed, in
addition to the routine popliteal and femoral veins investiga-
tion. The Paradoxical Embolism From Large Veins in Ische-
mic Stroke (PELVIS) study is ongoing to address these
preliminary observations.32
Direct arterial embolism of thrombus from the atrial
septum is another potential mechanism. In agreement with the
concept of “vascular bed-specific hemostasis” proposed by
Rosenberg and Aird,33 Kistler and coworkers hypothesized
that the rate of cardioembolic stroke might be the result of a
combination of anatomic and hemostatic defects.34 A sys-
temic prothrombotic state affecting the coagulation process
on the endocardial surface of the heart might be the first event
in the pathophysiological mechanism leading to “local throm-
bus” formation.33 The likelihood of this process and the rate
of subsequent embolism are expected to increase in subjects
carrying anatomic abnormalities within the heart such as a
PFO34,35 and might be even higher in the presence of
additional predisposing conditions such as transient atrial
arrhythmias.8
Our findings are apparently in disagreement with those of
the recent Patent Foramen Ovale in Cryptogenic Stroke Study
(PICSS) that showed no significant difference in the rate of
recurrent stroke or death between patients with PFO and
those with otherwise unexplained infarcts randomized to
warfarin or aspirin.36 If an association between PFO and
prothrombotic disorders in stroke patients exists, one would
theoretically expect a better response to oral anticoagulants
than to platelet inhibitors. However, because PICSS was not
specifically designed to explore the role of thrombophilic
disorders in patients with PFO, no detailed information on the
patients’ coagulative status is available. A further explanation
of this disagreement might be the age of the patients (59.0 and
34.7 years in PICSS and our series, respectively), which
might exert an effect on the relation between cardiac abnor-
malities and thrombophilic disorders. Finally, contrary to
PICSS, a recent meta-analysis found warfarin superior to
antiplatelets in preventing recurrent ischemic events in pa-
tients with PFO.37
Study Limitations
Some limitations of our study should be noted. First, PFO is
frequently associated with atrial septal aneurysm (ASA), and
the presence of both abnormalities, as opposed to PFO alone,
has been recently demonstrated to increase the risk of
TABLE 3. Distribution and Adjusted Odds Ratios of Prothrombotic Genotypes in PFO and PFO Patients
Genotype
PFO Patients
(n36)
PFO Patients
(n89)
PFO vs Controls PFO vs PFO
P Value*
Adjusted
OR 95% CI
Adjusted
OR 95% CI
FVG1691A 4 (11) 2 (2.2) NS NS NS NS 0.160
PTG20210A 4 (11) 1 (1.1) 0.19 0.04–0.94 10.09 1.09–109 0.047
TT MTHFR 7 (19.4) 20 (22.4) NS NS NS NS 0.337
FVG1691A or PTG20210A 7 (19.4) 3 (3.3) 0.24 0.08–0.75 6.16 1.45–26.1 0.021
FVG1691A or TT MTHFR 10 (27.8) 22 (24.7) NS NS NS NS 0.294
PTG20210A or TT MTHFR 10 (27.8) 21 (23.6) NS NS NS NS 0.339
FVG1691A or PTG20210A or TT MTHFR 12 (33.3) 23 (25.8) NS NS NS NS 0.115
Combined thrombophilic defects 3 (8.3) 0 (0.0) 0.09 0.01–0.66       0.015
*P values obtained using the Likelihood Ratio Test of Multinomial Logistic Regression Models for testing overall prothrombotic
genotypes effect. NS indicates not significant.
Pezzini et al Thrombophilic Disorders in PFO-Related Infarcts 31
recurrent stroke.38 The TCD technique prevents the assess-
ment of ASA, which represents the major drawback of the
present study. Any further analyses comparing the prevalence
of inherited thrombophilias in stroke patients with PFO,
ASA, or both are hindered by the lack of precise data on the
frequency of ASA in our series. Second, our protocol did not
include any measurement, albeit semiquantitative, of PFO
diameter, an anatomic marker that may allow the identifica-
tion of patients at high risk of embolism.39 However, because
of the anatomic characteristics of the foramen ovale, it is not
simple to obtain measures of the maximum size of the
opening with contrast TCD, and it might be that the micro-
bubble count does not reflect the exact amount of shunting.40
Finally, the lack of a systematic search for right-to-left shunt
in the group of controls hampers any comparisons between
the PFO subjects with stroke and those without stroke. The
clinical implications of these missing data are noteworthy, but
it seems unlikely that they have significantly altered the
results of our study.
Clinical Implications
Besides the potential impact on the understanding of the
pathophysiology of PFO-related infarcts, an additional impli-
cation of our findings concerns the evaluation of the appro-
priateness of coagulation testing in patients with ischemic
stroke and the selection of patients eligible for detailed
coagulation studies.41 Coagulation tests seem to be of little
value in the diagnostic workup of young patients with
ischemic stroke except in the small subgroup with PFO-
related infarct. Accordingly, laboratory testing for coagulopa-
thies in this specific subtype of stroke may be warranted and
cost-effective.
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